Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2a, Randomized, Double-Blind, Placebo-Controlled, Proof-of-Concept Study to Evaluate the Safety, Pharmacokinetics, and Clinical Activity of VYD2311 for the Treatment of Adults With Long-COVID or Post-Vaccination Syndrome (FLINTLOCK)

NCT07899346 is registered in ClinicalTrials.gov with Invivyd, Inc. as lead sponsor.

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, 14-day trial. Card required. Your first charge is when the trial ends. See pricing

Get the NCT07899346 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Follow this trial by email

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2a, Randomized, Double-Blind, Placebo-Controlled, Proof-of-Concept Study to Evaluate the Safety, Pharmacokinetics, and Clinical Activity of VYD2311 for the Treatment of Adults With Long-COVID or Post-Vaccination Syndrome (FLINTLOCK)
Lead sponsor
Invivyd, Inc.
Phase
Phase 2
Overall status
Not yet recruiting
Start date
October 31, 2026
Completion date
June 30, 2027
Enrollment
130 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

covid 19 vaccine, covid long, covid-19 (sars-cov-2 infection), long covid

Arms

As registered; 2 arms.

  • VYD2311 ExperimentalVYD2311

    Dosing via intravenous (IV) infusion on Day 1 follow by dosing via intramuscular (IM) injection on Day 30 and Day 60 with VYD2311

  • Placebo Placebo comparatorPlacebo

    Dosing via intravenous (IV) infusion on Day 1 follow by dosing via intramuscular (IM) injection on Day 30 and Day 60 with Placebo - 0.9% sodium chloride (normal saline)

Primary endpoints

Registered primary outcome measures; 2 primary.

  • Assessment of safety based on treatment emergent adverse events, injection site reactions, and hypersensitivity reactions through Day 90 90 days
  • Serum concentrations of VYD2311 through Day 90 90 days

Lead sponsor's other trials

Invivyd, Inc., most recent start first.

Similar trials

Same condition (Post-Acute COVID-19 Syndrome) and phase, most recent start first.